Aktiesnakken — April 2010
-
-
I lyset heraf
er den statistiske konklusion blevet revurderet, hvilket viser en formel
p-værdi på 0,042 for det primære endpoint, mMS med -
med indikation af, at det
prædefinerede 0,025 signifikanskrav (Bonferroni-justering), som anført i
protokollen ikke blev mødt. -
Derfor aktien falder? 154 nu
-
141-145 nu
-
what?
-
132-133
-
Den regulatoriske strategi for Huntexil
er uændret, og NeuroSearch vil indlede dialog med sundhedsmyndighederne baseret på resultaterne fra -
fra MermaiHD studiet
-
er det mon "dialog" der afskrækker investorerne?
-
120-121 nu
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind